Advertisement

Topics

Latest "Merck Química Argentina S.A.I.C." News Stories

08:49 EST 19th November 2018 | BioPortfolio

Here are the most relevant search results for "Merck Química Argentina S.A.I.C." found in our extensive news archives from over 250 global news sources.

More Information about Merck Química Argentina S.A.I.C. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Merck Química Argentina S.A.I.C. for you to read. Along with our medical data and news we also list Merck Química Argentina S.A.I.C. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Merck Química Argentina S.A.I.C. Companies for you to search.

Showing "Merck mica Argentina" News Articles 1–25 of 2,000+

Monday 19th November 2018

Atrium Innovations Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryAtrium Innovations Inc Atrium is a provider of sciencebased natural health products. The company develops, manufactures and markets nutritional and dietary supplements. Its major products include minerals, vitamins and specialized products such as enzymes and probiotics. Atrium markets its products under brands such as Garden of Life, Klean Athlete, Minami and Orthica, among others. It has...


Synthon Holdings BV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummarySynthon Holdings BV Synthon is an integrated pharmaceutical company which focuses on delivering affordable medicines through innovative science. The company undertakes the research, development, manufacture and distribution of generics, active pharmaceutical ingredients and biopharmaceutical products. It provides small molecule generic products in the therapeutic areas of allergy, antiinfec...

Merck erleidet Rückschlag mit Avelumab in Eierstockkrebs-Studie

FRANKFURT (Dow Jones)--Der Darmstädter Pharma- und Spezialchemiekonzern Merck hat mit seinem Hoffnungsträger Avelumab einen weiteren Rückschlag erlitten. Die klinische Phase-3-Studie Javelin Ovari...


Merck erleidet erneut Rückschlag mit Avelumab - Eierstockkrebs-Studie floppt

Weiterer Rückschlag für die Pharmakonzerne Merck KGaA und Pfizer : Das gemeinsam entwickelte Medikament Avelumab scheiterte in einer Studie an Patientinnen mit bestimmtem Eierstockkrebs. Wie die b...

Merck KGaA, Pfizer: JAVELIN Ovarian 200 Trial Did Not Meet Primary Endpoints

German drugmaker Merck KGaA (MKGAY.PK) and Pfizer Inc. (PFE) said Monday that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin or PLD, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival (OS) or progression-free survival (PFS) in patients with platinum-resistant or -ref...

Merck KGaA & PFE Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer #Fail https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-pfizer-121200230.html …

Merck KGaA & PFE Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer #Fail https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-pfizer-121200230.html …

Neue 10,55% PROTECT Multi Aktienanleihe auf Bayer, Merck und Sanofi in Zeichnung

München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue PROTECT Multi Aktienanleihe (ISIN DE000VA9KDS8/ WKN VA9KDS) auf die Aktien von Bayer ...

Barclays hebt Ziel für Merck KGaA auf 78 Euro - 'Underweight'

Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 72 auf 78 Euro angehoben, die Einstufung aber auf "Underweight" belassen. Nach den jüngst vorgelegten guten Zahlen sowie d...

ANALYSE-FLASH: Commerzbank hebt Ziel für Merck KGaA auf 111 Euro - 'Buy'

Die Commerzbank hat das Kursziel für Merck KGaA nach Quartalszahlen von 100 auf 111 Euro angehoben und die Einstufung auf "Buy" belassen. Der Pharma- und Chemiekonzern habe operative Stärke gezeig...

Immunicum (IMMU) - Collaboration and supply agreement signed

Edison Investment Research - Pharmaceutical & healthcare - Immunicum: Immunicum has announced that it has signed a collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and...

Friday 16th November 2018

MediWound Ltd MDWD Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryMediWound Ltd MediWound is a biopharmaceutical company that on develops, manufactures and commercializes novel therapeutics based on its patented proteolytic enzyme technology. Its products address unmet needs in the areas of severe burns, chronic and other hardtoheal wounds.The company's first innovative biopharmaceutical product, NexoBrid is approved for removal of damaged or dead tissue,...

Enzon Pharmaceuticals Inc ENZN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryEnzon Pharmaceuticals Inc Enzon, formerly Enzon, Inc., is a pharmaceutical company that receives royalty revenues from existing licensing arrangements. The company has licensing arrangements with other companies related to sales of their four marketed drug products, namely, PegIntron, Sylatron, Macugen and CIMZIA. Enzon sources its royalty revenues primarily through the sale of PegIntron, w...

Merck KGaA-Aktie: Geht es weiter nach oben?

Seit etwa Ende März befindet sich die Aktie des Chemie- und Pharmakonzerns Merck in einem Aufwärtstrend. Dabei gelangen seit dem 30. Oktober deutliche Zugewinne und infolgedessen auch der Sprung üb...

Croda International Plc CRDA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryCroda International Plc Croda is a chemical company, which produces and sells specialty chemicals. The company's product portfolio includes traditional and microwave plant extracts, active ingredients and cosmetic oils among others used in coatings polymers, crop care, geo technologies, health care, home care, industrial chemicals, lubricants, personal care and polymer additives. It offer...

Immunicum Collaborates with Merck KGaA and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial. Immunicum will initiate a study &#...

Mystic Miss Not Make Or Break For Imfinzi

While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is...   

AstraZeneca's immunotherapy fails in key lung cancer trial

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck & Co is enjoying huge sales success with Keytruda. How...

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

Press Release 16 November 2018 Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study Immunicum AB (publ; IMMU.ST) announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead ...

Attraktive Chancen - Aktienanleihen auf Merck KGaA, RWE, ThyssenKrupp

- Wichtige rechtliche Hinweise Um Ihnen die Suche und Auswahl attraktiver Aktienanleihen zu erleichtern, finden Sie hier eine Zusammenstellung an CLASSIC Aktienanleihen auf Einzelaktien. Die Auswa...

Thursday 15th November 2018

Global Hyperlipidemia Drugs Market Analysis (2016-2022): AstraZeneca, Merck, Pfizer, Daiichi ...

DUBLIN, Nov. 15, 2018 /PRNewswire/ -- The "Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Read more...

Patients are our top priority at @Merck – this is why we continue to address the broader affordability issues in our health system, while never relenting in our pursuit to invent new medicines. Learn more about our efforts: https://bit.ly/2OCVkxp  #In

Patients are our top priority at @Merck – this is why we continue to address the broader affordability issues in our health system, while never relenting in our pursuit to invent new medicines. Learn more about our efforts: https://bit.ly/2OCVkxp  #InventingForLife

The only way for patients to benefit from medicines is for companies like @Merck to invest in R&D. The breakthroughs of tomorrow depend on the willingness and ability to pay for medicines today: https://bit.ly/2OCVkxp 

The only way for patients to benefit from medicines is for companies like @Merck to invest in R&D. The breakthroughs of tomorrow depend on the willingness and ability to pay for medicines today: https://bit.ly/2OCVkxp 

ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics

The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma –...   

NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920

NewLink Genetics (NASDAQ:NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated). As quoted in the press release: This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July R...

2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo

The International Society for Pharmaceutical Engineering (ISPE) installed its 2018–2019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018–2019 ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks